1 With the largest group of LBCL patients treated with an Allogeneic ... yet' and could pave the way for successful Allogeneic treatments in the future. 2 Following the durable response data ...

In the following sections, I will be describing the challenges and opportunities of allogeneic CAR-T, Allogene’s pipeline updates, the competitive landscape ... the treatment of r/r LBCL.

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...

the current standard following first-line treatment for LBCL. That got the attention of Dr. Zachary Roberts, EVP, Research and Development and Chief Medical Officer at the CAR-T biotech Allogene ...